Innovators in Point of Care Diagnostics

About XING Technologies

XING Technologies is an Australian-based biotechnology company specialising in transformative diagnosis and monitoring technologies for cancer and disease. Its proprietary nanotechnologies are transforming the future practice of medicine and enabling personalised healthcare.


Ultra-fast COVID-19 test in the works in Australia

XING Technologies has designed a simple pregnancy dipstick test has received $1.5 million dollars from the State Government through the Palaszczuk Government's Industry Tech Fund to fast track the corona virus test.

XING Technologies has bio-engineered yeast molecules, coated with velcro-like particles that the virus sticks to and can detect whether a person is infected and contagious within 15 minutes. The technology known as XavTrap®, is a low-cost, rapid point-of-care test that has also recieved US$1 million funding from the US Government to reduce the spread of COVID-19.

XING Group Holdings has a clear vision in applying point-of-care diagnostic nanotechnologies to globally enhance healthcare systems. XING's service and product lines currently span from cancer care to rapid nucleic acid extraction, protein detection diagnostics, and nanoparticle capture agents to identify and prevent the spread of infectious diseases.

XING Diagnostics

  • Enabling rapid, cost-effective diagnostics with the potential for point-of-care nucleic acid detection of disease

  • Utilizes nanotechnology to perform a comprehensive analysis of nucleic acids in urine, blood, saliva & biopsy material

  • Portable equipment requiring minimal technical expertise and training

  • Provides an accurate measurement less than 30 minutes

  • Can perform multiple tests at once

  • Adaptable to all pathogens (bacteria, viruses, fungi, parasites) and cancer

XING Genomic Services

Provider for:

  • Whole genome sequencing

  • Whole exome sequencing

  • Targeted gene panels

  • RNA-Seq

  • meDNA profiling

  • Patient cohort studies

  • Bioinformatic analysis

  • Custom applications

XING Cancer Care

  • Guiding patients with their oncologists through cancer genomic testing to improve patient outcomes

  • Providing referring oncologists with ongoing information and support in cancer genomic testing and interpretation

  • Our XGP1000 Cancer Panel offers the most sophisticated genomic analysis in Australia

  • NATA ISO 15189 accredited

  • Expertise in translational genomics and precision medicine to expand offerings in monitoring, therapy recommendations, and disease prognosis